Revolution Medicines, Inc. (RVMD)

Revolution Medicines, Inc. (RVMD) Healthcare & Pipeline Overview

Revolution Medicines, Inc. is a clinical-stage precision oncology company pioneering therapies targeting RAS-addicted cancers. Their innovative pipeline of SHP2, SOS1, and mutant-selective KRAS inhibitors positions them at the forefront of addressing unmet needs in cancer treatment within the competitive biotechnology sector.

What Is the Investment Thesis for RVMD?

Revolution Medicines presents a notable research candidate due to its focus on the RAS pathway, a validated but challenging target in cancer therapy. The company's diverse pipeline of RAS inhibitors, including SHP2, SOS1, and mutant-selective KRAS inhibitors, offers multiple potential value drivers. Positive clinical data from ongoing Phase 1/2 trials of RMC-4630 could serve as a significant catalyst. The collaboration with Sanofi for SHP2 inhibitors further validates the company's technology and provides financial resources. However, the inherent risks associated with clinical-stage drug development, including trial failures and regulatory hurdles, should be considered. With a market capitalization of $40.25B and a beta of 1.01, RVMD reflects moderate market sensitivity.

Based on FMP financials and quantitative analysis

RVMD Key Highlights

• Revolution Medicines is focused on developing therapies to inhibit frontier targets in RAS-addicted cancers.
• RMC-4630, an inhibitor of SHP2, is in Phase 1/2 clinical trial for the treatment of solid tumors.
• The company is developing RMC-5845, a selective inhibitor of SOS1, a protein that converts RAS (OFF) to RAS (ON) in cells.
• Revolution Medicines is advancing RMC-6291, a mutant-selective inhibitor of KRASG12C(ON) and NRASG12C(ON).
• The company has a collaboration agreement with Sanofi for the research and development of SHP2 inhibitors, including RMC-4630.

Who Are RVMD's Competitors?

RVMD is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are RVMD's Key Strengths?

• Proprietary RAS-targeted drug discovery platform
• Diverse pipeline of RAS inhibitors
• Strategic collaboration with Sanofi
• Experienced management team

What Are RVMD's Weaknesses?

• Clinical-stage company with no approved products
• High R&D expenses
• Reliance on clinical trial outcomes
• Competition from larger pharmaceutical companies

What Could Drive RVMD Stock Higher?

• Data readout from Phase 1/2 clinical trial of RMC-4630 in solid tumors (2027).
• Preclinical and early clinical data for RMC-5845 (late 2026).
• Potential initiation of Phase 1 clinical trial for mutant-selective KRAS inhibitor RMC-6291 (2028).
• Advancement of RAS(ON) Inhibitors targeting KRASG13C(ON) and KRASG12D(ON).
• Continued collaboration with Sanofi for the research and development of SHP2 inhibitors.

What Are the Key Risks for RVMD?

• Negative return on equity (-83.2%) — the business is not currently generating profit on shareholder capital.
• Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
• Clinical trial failures for RMC-4630 and other pipeline assets.
• Regulatory delays or rejection of drug candidates.
• Competition from other companies developing RAS-targeted therapies.
• Patent challenges or expiration of key patents.
• High R&D expenses and potential need for additional financing.

What Are the Growth Opportunities for RVMD?

• Expansion of RMC-4630 Clinical Trials: Revolution Medicines can expand the clinical trials for RMC-4630 to include a broader range of solid tumors and combination therapies. The global solid tumor market is projected to reach $450 billion by 2028, offering a significant opportunity for RMC-4630 if it demonstrates efficacy across multiple cancer types. Success in these trials, expected to yield initial data in 2027, would significantly increase the drug's market potential and accelerate revenue growth.
• Advancement of SOS1 Inhibitor RMC-5845: The development of RMC-5845, a selective inhibitor of SOS1, presents a growth opportunity by targeting RAS activation. The market for drugs targeting RAS signaling is expected to grow rapidly, driven by the high prevalence of RAS mutations in cancer. Positive preclinical and early clinical data for RMC-5845, anticipated by late 2026, could attract further investment and partnerships, expanding the company's pipeline and market reach.
• Development of Mutant-Selective KRAS Inhibitors: Revolution Medicines' focus on developing mutant-selective KRAS inhibitors, such as RMC-6291, addresses a critical unmet need in cancer treatment. KRAS mutations are common in various cancers, and selective inhibitors offer the potential for more effective and less toxic therapies. Successful development and commercialization of these inhibitors, with potential market entry by 2029, could generate substantial revenue and establish the company as a leader in RAS-targeted therapies.
• Strategic Collaborations and Partnerships: Revolution Medicines can pursue additional strategic collaborations and partnerships with pharmaceutical companies to accelerate the development and commercialization of its pipeline assets. The existing collaboration with Sanofi for SHP2 inhibitors demonstrates the value of such partnerships. Expanding these collaborations, potentially starting in 2027, could provide access to additional funding, expertise, and market access, enhancing the company's growth prospects.
• Expansion into New RAS Targets: Revolution Medicines can leverage its expertise in RAS biology to expand its pipeline into new RAS targets and related signaling pathways. This could involve developing inhibitors for other RAS isoforms or targeting downstream effectors of RAS signaling. By diversifying its pipeline, the company can reduce its reliance on individual drug candidates and create a more sustainable growth trajectory. Research and development efforts in this area are expected to intensify by 2028, potentially leading to new drug candidates in the early 2030s.

What Opportunities Does RVMD Have?

• Expansion of clinical trials for RMC-4630
• Development of mutant-selective KRAS inhibitors
• Strategic collaborations and partnerships
• Expansion into new RAS targets

What Threats Does RVMD Face?

• Clinical trial failures
• Regulatory hurdles
• Competition from other RAS-targeted therapies
• Patent expiration

What Are RVMD's Competitive Advantages?

• Proprietary RAS-targeted drug discovery platform.
• Strong intellectual property portfolio protecting its drug candidates.
• Strategic collaboration with Sanofi for SHP2 inhibitors.
• Expertise in RAS biology and drug development.

What Does RVMD Do?

Revolution Medicines, Inc., founded in 2014 and headquartered in Redwood City, California, is a clinical-stage precision oncology company dedicated to discovering and developing novel therapies that inhibit frontier targets in RAS-addicted cancers. The company's mission is to transform cancer treatment by focusing on the RAS pathway, a critical driver of many human cancers. Revolution Medicines is developing a portfolio of innovative drug candidates designed to selectively target and inhibit various nodes within the RAS signaling network. Their lead product candidate, RMC-4630, is an inhibitor of SHP2, a protein involved in RAS signaling, currently in Phase 1/2 clinical trials for treating solid tumors, including gynecologic and colorectal cancers. Other pipeline assets include RMC-5845, a selective inhibitor of SOS1, which plays a crucial role in activating RAS, and RMC-5552, a hyperactivated selective inhibitor of mTORC1 signaling in tumors. Furthermore, the company is advancing RMC-6291, a mutant-selective inhibitor of KRASG12C(ON) and NRASG12C(ON), and RMC-6236, a RAS-selective inhibitor of multiple RAS(ON) variants. Revolution Medicines also develops RAS(ON) Inhibitors targeting KRASG13C(ON) and KRASG12D(ON). The company has a strategic collaboration agreement with Sanofi for the research and development of SHP2 inhibitors, including RMC-4630, enhancing its development capabilities and market reach.

What Products and Services Does RVMD Offer?

• Develop therapies to inhibit frontier targets in RAS-addicted cancers.
• Develop RMC-4630, an inhibitor of SHP2, for the treatment of solid tumors.
• Develop RMC-5845, a selective inhibitor of SOS1, a protein that converts RAS (OFF) to RAS (ON) in cells.
• Develop RMC-5552, a hyperactivated selective inhibitor of mTORC1 signaling in tumors.
• Develop RMC-6291, a mutant-selective inhibitor of KRASG12C(ON) and NRASG12C(ON).
• Develop RMC-6236, a RAS-selective inhibitor of multiple RAS(ON) variants.
• Develop RAS(ON) Inhibitors targeting KRASG13C(ON) and KRASG12D(ON).

How Does RVMD Make Money?

• Develops and patents novel cancer therapies targeting the RAS pathway.
• Conducts preclinical and clinical trials to evaluate the safety and efficacy of drug candidates.
• Partners with pharmaceutical companies for research, development, and commercialization.
• Generates revenue through licensing agreements and potential future product sales.

What Industry Does RVMD Operate In?

Revolution Medicines operates within the competitive biotechnology industry, which is characterized by high R&D spending, lengthy development timelines, and significant regulatory oversight. The company's focus on RAS-addicted cancers aligns with a growing trend in precision oncology, where therapies are tailored to specific genetic mutations. The RAS pathway is implicated in approximately 30% of all human cancers, representing a substantial market opportunity. Competitors like ROIV: Roivant Sciences Ltd. and MRNA: Moderna, Inc. are also active in oncology, but Revolution Medicines differentiates itself through its specific focus on RAS inhibition.

Who Are RVMD's Key Customers?

• Patients with RAS-addicted cancers.
• Oncologists and other healthcare professionals.
• Pharmaceutical companies through collaborations and licensing agreements.

ROE -83%Key Financial Metrics

Return on equity for Revolution Medicines, Inc. stands at -83.2%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -60.9%, showing how much profit it generates from its asset base. Its free cash flow yield is -2.7%, a gauge of the cash the business throws off relative to its market value. A current ratio of 6.80 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -3.7%, the inverse of the P/E and a quick read on earnings relative to price.

Revolution Medicines, Inc. (RVMD) Valuation Context

Valued at $40.25B, RVMD is classified as a large-cap stock. Relative to its peer group, RVMD's quantitative score of 56/100 is above the peer average of 40/100.

Company Profile

Revolution Medicines, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Redwood City, US. The company is led by CEO Mark A. Goldsmith. RVMD has traded publicly since 2020.

F-Score 1/9Financial Health

Revolution Medicines, Inc.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 28.90 places it in the safe zone, indicating low near-term bankruptcy risk.

FY2026 estForward Outlook

Wall Street analysts project Revolution Medicines, Inc. revenue of about $103.7M for fiscal 2026, with EPS near $-7.95. The estimate reflects 16 contributing analysts.

Net buyingInsider Activity

Over the past six months, Revolution Medicines, Inc. insiders filed 30 SEC Form 4 transactions — 14 sales and 16 purchases. On net that is roughly 42K shares acquired (about $615K) — insiders putting money in tends to read as conviction.

RVMD Financials

RVMD Latest News

RVMD Analyst Consensus

RVMD MoonshotScore

Latest Revolution Medicines, Inc. Analysis

Revolution Medicines, Inc. Healthcare Stock: Key Questions Answered

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources